Orogen Therapeutics partners with Excelra for GOSTAR®

Hyderabad, India / Woburn, Mass - 13 December 2024 - Excelra, a leading global data and digital insights organization, has announced a partnership with Orogen Therapeutics, an innovative DNA-Encoded Library (DEL) & Artificial Intelligence (AI)-driven biotechnology company, currently engaged in developing a portfolio of best-in-class small molecule treatments.

Integrating Excelra’s GOSTAR datasets enhances Orogen Therapeutics’ advanced drug discovery platform, which combines DEL with AI/ML and molecular simulations. This infusion of curated digital knowledge will expedite lead identification, optimization, and candidate selection. By unlocking the value within the GOSTAR data, the collaboration will be at the forefront of predicting chemical, biological, and physicochemical properties of novel compounds, accelerating the time- and resource-intensive stages of drug discovery.

Dr Artem Evdokimov, Head of Research at Orogen Therapeutics said:

Partnership with Excelra strengthens our position to deliver innovative clinical value to patients by leveraging curated prior art data in synergy with experimental science, AI, and new biology. We are very excited to add Excelra’s GOSTAR to our arsenal of tools, as it is the industry gold standard in structured SAR intelligence. This addition will enhance our AI/ML platform to rapidly iterate and confidently simulate outcomes, thereby delivering effective therapies for patients with serious diseases.

“Technologies such as AI/ML and quantum simulation are accelerating the development of therapies, and GOSTAR helps break a critical bottleneck in predictive modeling for drug discovery by providing high-quality, clean, and annotated datasets. As a result, biotechs and AI/ML companies are able to rapidly simulate and clearly identify patterns and extrapolate those findings into potential new areas of discovery,” said Norman Azoulay, Vice President, Platforms and Data, Excelra.